Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$203731.0.

  • Regenerative Medical Technology's Cash from Operations fell 17464.26% to -$203731.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$365322.0, marking a year-over-year decrease of 18266.94%. This contributed to the annual value of $850699.0 for FY2024, which is 30293.44% up from last year.
  • Regenerative Medical Technology's Cash from Operations amounted to -$203731.0 in Q3 2025, which was down 17464.26% from -$598093.0 recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Cash from Operations registered a high of $379393.0 during Q4 2024, and its lowest value of -$8.7 million during Q4 2021.
  • For the 5-year period, Regenerative Medical Technology's Cash from Operations averaged around -$598722.5, with its median value being -$151941.0 (2022).
  • As far as peak fluctuations go, Regenerative Medical Technology's Cash from Operations tumbled by 892508.69% in 2021, and later soared by 259226.67% in 2024.
  • Over the past 5 years, Regenerative Medical Technology's Cash from Operations (Quarter) stood at -$8.7 million in 2021, then soared by 98.64% to -$118893.0 in 2022, then soared by 75.27% to -$29399.0 in 2023, then skyrocketed by 1390.5% to $379393.0 in 2024, then tumbled by 153.7% to -$203731.0 in 2025.
  • Its Cash from Operations was -$203731.0 in Q3 2025, compared to -$598093.0 in Q2 2025 and $57109.0 in Q1 2025.